Since a child, I always loved to learn and I was very keen on learning mathematics and science. I did not come from a family of scientists, though. My dad was very good with mathematics, and I loved to give him mental arithmetic to challenge him--and he was always right with his answers!
Targeting Complement to Reduce Disease Activity: Quantitative Systems Pharmacology (QSP) to Enhance Efficient Drug Development (Part One)
Deficiency or dysfunction in regulatory factors that control the complement cascade critically contribute to several rare diseases...
Exploring Lead-Like Molecules of Traditional Chinese Medicine for Treatment Quest against Aliarcobacter butzleri: In Silico Toxicity Assessment, Dynamics Simulation, and Pharmacokinetic Profiling
Aliarcobacter butzleri is a Gram-negative, curved or spiral-shaped, microaerophilic bacterium and causes human infections, specifically diarrhea, fever, and sepsis.
Best of Both Worlds: An Expansion of the State of the Art pKa Model with Data from Three Industrial Partners
In a unique collaboration between Simulations Plus and several industrial partners, we were able to develop a new version 11.0 of the previously published1 in silico pKa model, S+pKa, with considerably improved prediction accuracy.
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20
Construction of a Simulated Population of Post-Menopausal Women for the Prediction of Drug-Induced Liver Injury (DILI)
ASCPT 2024: Construction of a Simulated Population of Post-Menopausal Women for the Prediction of Drug-Induced Liver Injury (DILI)
A Biomarker-Focused QSP Model of Complement Alternative and Terminal Pathways to Evaluate Potential Targets for Therapeutic Impact in Complement-Associated Diseases: Paroxysmal Nocturnal Hemoglobinuria (PNH) as a Case Study
Complement overactivity has been implicated in multiple diseases, including PNH...
Optimizing Obesity Treatments: 3 Ways to Accelerate Your Program
As a nutritional biochemist by training, I am really excited about the effectiveness of current treatments for obese patients—and it extends well beyond weight loss.
Framework for Classifying Chemicals for Repeat Dose Toxicity using NAMs
Initially all chemicals are of High concern. Reassessment is based on accumulating evidence to potentially move chemicals to Medium or Low concern.
International Perspectives on Model-Informed Precision Dosing: From the Data to the Patients
Identifying the right dose of the right drug for the right patient is a central objective of pharmaceutical drug development.
QSP in the Real World: Where Has Quantitative Systems Pharmacology (QSP) Been Used to Support Drug Development and With What Impact?
Quantitative systems pharmacology (QSP) is gaining acceptance and utilization in many drug development programs, but even those who appreciate its value may not fully recognize the extent to which it has already achieved impact and/or its range of potential applications.
Unlocking the Power of PBPK Modeling: PBPK for First-in-Human and Beyond
The mechanistic translation of nonclinical pharmacokinetic data to humans can make or break the success of your clinical plan.
Evaluating Immune Checkpoint Inhibitors for Liver Toxicity in a Biomimetic Liver Microphysiology Model
The prominence of biologic drugs has rapidly gained traction and has delivered life-changing...
Lunch & Learn – SOT 63rd Annual Meeting and ToxExpo
SOT 2024: What's New at Simulations Plus, Your Partner in Winning, for Exposure and Safety Assessment
Investigating the Potential Hepatotoxicity of ORM-48824 in a Quantitative Systems Toxicology Platform for Liver Safety, DILIsym®
ORM-48824 is a transient receptor potential Ankyrin-1 (TRPA1) antagonist and was initially being developed for patients with diabetic neuropathic pain...
Prediction of Multidrug Resistance Protein 3 (MDR3) Inhibition-mediated Cholestatic Drug-induced Liver Injury (DILI) Using Quantitative Systems Toxicology (QST) Modeling
DILI is a primary cause of acute liver failure and reason for the termination of drug development programs...
Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended-Release and Immediate-Release Formulations with DILIsym, a Quantitative Systems Toxicology (QST) Software Platform
The analgesic/antipyretic acetaminophen (APAP) has multiple formulations including immediate-, modified-, and extended-release preparations...